Global coagulation assays display variable effects at different concentrations of rivaroxaban. The aim of this study is to quantify the ex vivo effects of low-dose rivaroxaban on thrombophilia screening assays and coagulation factor activities based on the administration time, and to show how to mask possible interferences. Plasma samples from 40 patients receiving rivaroxaban 10 mg daily we...

Two structurally different forms of activated human Factor IX (Factor IXaa and IXa8) have been previously reported to have essentially identical clotting activity in vitro. Although it has been shown that activated Factor IXChapel Hills an abnormal Factor IX isolated from the plasma of a patient with mild hemophilia B, and normal Factor IXaa are structurally very similar, the clotting activity ...

conclusions an hb-driven algorithm, in combination with the “coagulation box” and the early use of clotting factors, could be a simple and effective tool for improving coagulopathy in multiple trauma patients. results over a 12-month investigation period, 123 severe multiple trauma patients needing intensive care therapy were admitted to our trauma center (mean age 48 years, mean iss (injury se...

An artificial clotting system deficient in factor VIII has been made from normal human plasma. Factors XII and XI are supplied as ;activation product'. An eluate from Al(OH)(3), which has been incubated with normal plasma, supplies factors X and IX in their ;plasma' (unactivated) form with II. Factor V is provided as the supernatant after the Al(OH)(3)- treated plasma has been precipitated at o...